INVO Fertility, Inc. (IVF) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
57/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseIVF / S&P -30.15% / 15.20% |
LoseIVF / S&P 13.19% / 15.00% |
LoseIVF / S&P -106.19% / 50.40% |
| 2026-Q10/3 |
LoseIVF / S&P -27.76% / -4.33% |
LoseIVF / S&P 8.95% / 11.30% |
LoseIVF / S&P -101.44% / 27.70% |
| 2025-Q40/3 |
LoseIVF / S&P -87.62% / 2.65% |
LoseIVF / S&P 4.34% / 9.00% |
LoseIVF / S&P -10.68% / 13.40% |
| 2025-Q32/3 |
LoseIVF / S&P -71.21% / 8.12% |
WinIVF / S&P 12.04% / 4.61% |
WinIVF / S&P 6990.47% / 13.45% |
| 2025-Q22/3 |
LoseIVF / S&P -56.00% / 10.94% |
WinIVF / S&P 15.32% / 4.83% |
WinIVF / S&P 8113.59% / 10.63% |
| 2025-Q12/3 |
LoseIVF / S&P -79.42% / -4.27% |
WinIVF / S&P 55.96% / 4.98% |
WinIVF / S&P 9822.11% / 10.57% |
| 2024-Q43/3 |
WinIVF / S&P 14.08% / 2.41% |
WinIVF / S&P 117.21% / 5.25% |
WinIVF / S&P 5325.10% / 6.15% |
| 2024-Q32/3 |
LoseIVF / S&P -15.48% / 5.89% |
WinIVF / S&P 224.88% / 5.89% |
WinIVF / S&P 759.47% / 6.11% |
| 2024-Q22/3 |
LoseIVF / S&P -25.66% / 4.28% |
WinIVF / S&P 390.03% / 5.38% |
WinIVF / S&P 480.19% / 5.12% |
| 2024-Q12/3 |
LoseIVF / S&P -16.30% / 10.56% |
WinIVF / S&P 321.67% / 5.71% |
WinIVF / S&P 317.64% / 5.59% |
| 2023-Q43/3 |
WinIVF / S&P 70.89% / 11.69% |
WinIVF / S&P 267.38% / 6.81% |
WinIVF / S&P 411.18% / 7.78% |
| 2023-Q31/3 |
LoseIVF / S&P -80.25% / -3.27% |
LoseIVF / S&P -46.64% / 7.52% |
WinIVF / S&P 37.74% / -5.03% |
| 2023-Q21/3 |
LoseIVF / S&P -68.70% / 8.74% |
LoseIVF / S&P -67.07% / 9.50% |
WinIVF / S&P 214.23% / -8.57% |
| 2023-Q12/3 |
WinIVF / S&P 50.71% / 7.50% |
LoseIVF / S&P -72.30% / 10.77% |
WinIVF / S&P 2762.30% / -15.69% |
| 2022-Q41/3 |
LoseIVF / S&P -60.00% / 7.56% |
LoseIVF / S&P -80.24% / 11.88% |
WinIVF / S&P 2057.14% / -17.99% |
| 2022-Q33/3 |
WinIVF / S&P 65.63% / -4.88% |
WinIVF / S&P 174.55% / 13.47% |
WinIVF / S&P 615.08% / -1.41% |
| 2022-Q22/3 |
LoseIVF / S&P -75.76% / -16.10% |
WinIVF / S&P 150.82% / 13.71% |
WinIVF / S&P 266.67% / 11.04% |
| 2022-Q11/3 |
LoseIVF / S&P -20.72% / -4.60% |
WinIVF / S&P 148.64% / 15.97% |
LoseIVF / S&P -58.78% / 42.23% |
| 2021-Q41/3 |
LoseIVF / S&P 2.15% / 11.03% |
WinIVF / S&P 301.06% / 15.00% |
LoseIVF / S&P -58.55% / 96.40% |
| 2021-Q31/3 |
LoseIVF / S&P -29.89% / 0.58% |
WinIVF / S&P 11.90% / 10.77% |
LoseIVF / S&P 16.67% / 69.42% |
| 2021-Q22/3 |
LoseIVF / S&P 7.39% / 8.55% |
WinIVF / S&P 25.41% / 6.58% |
WinIVF / S&P 58.62% / 51.81% |
| 2021-Q12/3 |
WinIVF / S&P 43.85% / 6.17% |
LoseIVF / S&P -5.56% / -1.06% |
WinIVF / S&P 134.92% / 7.39% |
| 2020-Q41/3 |
LoseIVF / S&P IVF unavailable / 12.15% |
LoseIVF / S&P -29.92% / -3.72% |
WinIVF / S&P 347.06% / -33.42% |
| 2020-Q32/3 |
LoseIVF / S&P IVF unavailable / 8.93% |
WinIVF / S&P 33.90% / -2.04% |
WinIVF / S&P 500.00% / -27.10% |
| 2020-Q22/3 |
LoseIVF / S&P IVF unavailable / 20.54% |
WinIVF / S&P 63.63% / -0.46% |
WinIVF / S&P 2800.00% / -27.11% |
| 2020-Q12/3 |
LoseIVF / S&P IVF unavailable / -19.60% |
WinIVF / S&P 959.08% / 3.47% |
WinIVF / S&P 6200.00% / -14.75% |
| 2019-Q42/3 |
LoseIVF / S&P IVF unavailable / 9.07% |
WinIVF / S&P 2326.58% / 5.36% |
WinIVF / S&P 3300.00% / 2.99% |
| 2019-Q32/3 |
LoseIVF / S&P IVF unavailable / 1.70% |
WinIVF / S&P 107.55% / 5.02% |
WinIVF / S&P 1700.00% / 0.21% |
| 2019-Q22/3 |
LoseIVF / S&P IVF unavailable / 4.30% |
WinIVF / S&P 90.90% / 6.64% |
WinIVF / S&P 200.00% / 8.65% |
| 2019-Q10/3 |
LoseIVF / S&P IVF unavailable / 13.65% |
LoseIVF / S&P -56.21% / 8.12% |
LoseIVF / S&P IVF unavailable / 14.29% |
| 2018-Q40/3 |
LoseIVF / S&P IVF unavailable / -13.52% |
LoseIVF / S&P -78.38% / 9.05% |
LoseIVF / S&P IVF unavailable / 18.23% |
| 2018-Q31/3 |
LoseIVF / S&P IVF unavailable / 7.71% |
WinIVF / S&P 100.06% / 10.21% |
LoseIVF / S&P 0.00% / 19.06% |
| 2018-Q21/3 |
LoseIVF / S&P IVF unavailable / 3.43% |
WinIVF / S&P 127.57% / 9.03% |
LoseIVF / S&P 0.00% / 14.46% |
| 2018-Q11/3 |
LoseIVF / S&P IVF unavailable / -0.76% |
WinIVF / S&P 292.84% / 7.68% |
LoseIVF / S&P -100.00% / 12.46% |
| 2017-Q41/3 |
LoseIVF / S&P IVF unavailable / 6.64% |
WinIVF / S&P 454.30% / 7.03% |
LoseIVF / S&P -100.00% / 13.82% |
| 2017-Q31/3 |
LoseIVF / S&P IVF unavailable / 4.48% |
WinIVF / S&P 408.18% / 5.68% |
LoseIVF / S&P 0.00% / 17.57% |
| 2017-Q21/3 |
LoseIVF / S&P IVF unavailable / 3.09% |
WinIVF / S&P 513.51% / 4.83% |
LoseIVF / S&P 0.00% / 17.74% |
| 2017-Q11/3 |
LoseIVF / S&P IVF unavailable / 6.07% |
WinIVF / S&P 224.92% / 3.67% |
LoseIVF / S&P -50.00% / 13.32% |
| 2016-Q41/3 |
LoseIVF / S&P IVF unavailable / 3.82% |
WinIVF / S&P 335.46% / 2.09% |
LoseIVF / S&P -50.00% / 7.05% |
| 2016-Q31/3 |
LoseIVF / S&P IVF unavailable / 3.85% |
WinIVF / S&P 254.04% / 0.20% |
LoseIVF / S&P -83.33% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IVF total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.32% | 20.78% |
| Annualized return | -97.32% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IVF total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 83.14% |
| Annualized return | -90.18% | 12.86% |
10Y · 2020-11-02 to 2026-08-27
| Metric | IVF total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -72.60% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |